Author | Eva Carrasco, MD

Articles

Biweekly Gemcitabine, Doxorubicin, and Paclitaxel as First-Line Treatment in Metastatic Breast Cancer

February 01, 2001

ByPedro Sánchez-Rovira, MD, PhD

Margarita Fernández, MD

Maximiliano Martos, MD

Ana Lozano, MD

Eva Carrasco, MD

In a single-center, open, phase II trial, we assessed the toxicity and activity of a triple combination therapy-doxorubicin at 30 mg/m2 (day 1), paclitaxel (Taxol) at 135 mg/m2 (day 2), and gemcitabine (Gemzar) at 2,500 mg/m2